신규한비바이러스성유전자전달체및그제조방법

    公开(公告)号:KR100345250B1

    公开(公告)日:2003-01-15

    申请号:KR1019980020709

    申请日:1998-06-03

    Abstract: PURPOSE: A method of delivering genes into various liver cancer cells using virus-like particles (VLP) is provided to improve delivering efficiency by binding a gene to VLP then treating with polyoxyethylene-polyoxypropylene block copolymer. CONSTITUTION: A method comprises the following steps of: producing VLP from recombinant protein obtained by infecting Papillomavirus capsid antigen or other virus capsid antigen into insect cells; producing VLP-PL conjugate by conjugating polylysine with VLP; obtaining VLP-PL-pCMV beta-gal plasmid complex, VLP-PL-pSV2CAT plasmid complex or VLP-PL-pCMV-p53 plasmid complex by linking plasmid pCMV beta-gal, pSV2CAT, pCMV-p53, respectively; treating the complex with polyoxyethylene-polyoxypropylene block copolymer before transfecting into liver cancer cell line.

    Abstract translation: 目的:提供使用病毒样颗粒(VLP)将基因递送至各种肝癌细胞的方法,以通过将基因结合至VLP然后用聚氧乙烯 - 聚氧丙烯嵌段共聚物处理来提高递送效率。 构成:一种方法包括以下步骤:从通过将乳头瘤病毒衣壳抗原或其他病毒衣壳抗原感染到昆虫细胞中获得的重组蛋白产生VLP; 通过将聚赖氨酸与VLP缀合产生VLP-PL缀合物; 通过分别连接质粒pCMVβ-gal,pSV2CAT,pCMV-p53获得VLP-PL-pCMVβ-gal质粒复合物,VLP-PL-pSV2CAT质粒复合物或VLP-PL-pCMV- 在转染入肝癌细胞系之前用聚氧乙烯 - 聚氧丙烯嵌段共聚物处理复合物。

    비형간염바이러스엑스단백질에대한아이지엠단일클론항체및이를포함하는간질환진단용조성물
    2.
    发明授权
    비형간염바이러스엑스단백질에대한아이지엠단일클론항체및이를포함하는간질환진단용조성물 失效
    用于诊断包含其中的HEPATITIS B VI RUS及其组合物的组合物的IGMMONOCLONAL抗体

    公开(公告)号:KR100275865B1

    公开(公告)日:2000-12-15

    申请号:KR1019970048582

    申请日:1997-09-24

    Abstract: PURPOSE: Provided is IgM monoclonal antibody which shows specificity to X protein of hepatitis B virus and is useful in detecting cancer cells, and measuring the level of antigens and antibodies in blood. Also, hepatitis diagnosis composition that contains the monoclonal antibody is provided. CONSTITUTION: IgM monoclonal antibody is obtained by the next steps of: i) inserting SP2/0 X-02M (KCTC 0346BP) into a rat and obtaining spleen cells after 4 weeks; ii) mixing mouse spleen cells with myeloma cells and centrifuging the cells to obtain cell lysates; iii) facilitating the growth of hybridoma in HT medium; iv) selecting hybridoma cells which produces IgM monoclonal antibody through ELISA (Enzyme Linked Immunosorbent Assay); v) separating and purifying anti-X monoclonal antibody IgM; and vi) measuring the absorbency of anti-X monoclonal antibody IgM.

    Abstract translation: 目的:提供对乙型肝炎病毒X蛋白特异性的IgM单克隆抗体,可用于检测癌细胞,并测量血液中的抗原和抗体水平。 另外,提供含有单克隆抗体的肝炎诊断组合物。 构成:通过以下步骤获得IgM单克隆抗体:i)将SP2 / 0X-02M(KCTC 0346BP)插入大鼠中并在4周后获得脾细胞; ii)将小鼠脾细胞与骨髓瘤细胞混合并离心细胞以获得细胞裂解液; iii)促进HT培养基中杂交瘤的生长; iv)通过ELISA(Enzyme Linked Immunosorbent Assay)选择产生IgM单克隆抗体的杂交瘤细胞; v)分离纯化抗X单克隆抗体IgM; 和vi)测量抗X单克隆抗体IgM的吸光度。

    간암세포타겟팅용비바이러스성유전자전달체를이용한유전자전달방법
    3.
    发明公开
    간암세포타겟팅용비바이러스성유전자전달체를이용한유전자전달방법 失效
    用于靶向肝癌细胞的新型非病毒载体及其制备

    公开(公告)号:KR1020000001252A

    公开(公告)日:2000-01-15

    申请号:KR1019980021433

    申请日:1998-06-10

    CPC classification number: C12N15/85 C07K14/47

    Abstract: PURPOSE: A method of delivering genes into liver cancer cells is provided by using ASOR (asialoorosomucoid), a gene carrier, which binds to ASGPr (asialoglycoprotein receptor) uniquely existing in a liver cancer cell. CONSTITUTION: The method comprises the following steps of: producing ASOR-PL conjugate by conjugating polylysine with ASOR; obtaining ASOR-PL-pCMV beta-gal plasmid complex, ASOR-PL-pSV2CAT plasmid complex or ASOR-PL-pCMV-p53 plasmid complex by linking plasmid pCMV beta-gal, pSV2CAT, pCMV-p53, respectively; treating the complex with polyoxyethylene-polyoxypropylene block copolymer before transfecting into liver cancer cell line.

    Abstract translation: 目的:通过使用与ASGPr(脱唾液酸糖蛋白受体)独特存在的肝癌细胞中结合的ASOR(asialosomalosomal)(基因载体)提供将基因输送到肝癌细胞中的方法。 构成:该方法包括以下步骤:通过将聚赖氨酸与ASOR缀合产生ASOR-PL缀合物; 分别通过连接质粒pCMVβ-gal,pSV2CAT,pCMV-p53获得ASOR-PL-pCMVβ-gal质粒复合物,ASOR-PL-pSV2CAT质粒复合物或ASOR-PL-pCMV-p53质粒复合物; 在转染肝癌细胞株前用聚氧乙烯 - 聚氧丙烯嵌段共聚物处理复合物。

    신규한비바이러스성유전자전달체및그제조방법
    4.
    发明公开
    신규한비바이러스성유전자전달체및그제조방법 失效
    新型非病毒载体及其制备

    公开(公告)号:KR1020000000844A

    公开(公告)日:2000-01-15

    申请号:KR1019980020709

    申请日:1998-06-03

    CPC classification number: C12N15/866 A61K38/162 A61K39/12

    Abstract: PURPOSE: A method of delivering genes into various liver cancer cells using virus-like particles (VLP) is provided to improve delivering efficiency by binding a gene to VLP then treating with polyoxyethylene-polyoxypropylene block copolymer. CONSTITUTION: A method comprises the following steps of: producing VLP from recombinant protein obtained by infecting Papillomavirus capsid antigen or other virus capsid antigen into insect cells; producing VLP-PL conjugate by conjugating polylysine with VLP; obtaining VLP-PL-pCMV beta-gal plasmid complex, VLP-PL-pSV2CAT plasmid complex or VLP-PL-pCMV-p53 plasmid complex by linking plasmid pCMV beta-gal, pSV2CAT, pCMV-p53, respectively; treating the complex with polyoxyethylene-polyoxypropylene block copolymer before transfecting into liver cancer cell line.

    Abstract translation: 目的:提供使用病毒样颗粒(VLP)将基因递送到各种肝癌细胞中的方法,以通过将基因与VLP结合然后用聚氧乙烯 - 聚氧丙烯嵌段共聚物进行处理来提高递送效率。 构成:一种方法包括以下步骤:通过将乳头瘤病毒衣壳抗原或其他病毒衣壳抗原感染到昆虫细胞中而获得的重组蛋白中产生VLP; 通过将聚赖氨酸与VLP缀合产生VLP-PL缀合物; 分别通过连接质粒pCMVβ-gal,pSV2CAT,pCMV-p53获得VLP-PL-pCMVβ-gal质粒复合物,VLP-PL-pSV2CAT质粒复合物或VLP-PL-pCMV-p53质粒复合物; 在转染肝癌细胞株前用聚氧乙烯 - 聚氧丙烯嵌段共聚物处理复合物。

    간암세포타겟팅용비바이러스성유전자전달체를이용한유전자전달방법
    5.
    发明授权
    간암세포타겟팅용비바이러스성유전자전달체를이용한유전자전달방법 失效
    使用肝细胞靶向病毒基因载体的基因转移方法

    公开(公告)号:KR100330135B1

    公开(公告)日:2002-12-26

    申请号:KR1019980021433

    申请日:1998-06-10

    Abstract: 본 발명은 간암세포에 특이적으로 존재하는 ASGPr(asialoglycoprotein receptor)과 결합하는 ASOR(asialoorosomucoid)을 유전자전달체로 사용하여 간암세포주를 타겟팅하므로 유전자를 전달하는 유전자 전달방법 및 그 유전자 전달체에 관한 것이다.
    본 발명은 간세포에 특이적으로 존재하는 것으로 알려진 ASGPr(asialoglycoprotein receptor)과 결합하는 ASOR(asialoorosomucoid)에 폴리라이신(PL)을 콘주게이션하여 ASOR-PL 콘주게이트를 제조하고 플라스미드 pSV2CAT, pCMV β-gal, pCMV-p53를 각각 결합시켜 ASOR-PL-pSV2CAT 플라스미드 콤플렉스, ASOR-PL-pCMV β-gal 플라스미드 콤플렉스, ASOR-PL-pCMV-p53 플라스미드 콤플렉스를 얻은 후 이를 다양한 간암세포주에 넣어 유전자를 전달하고 이때 폴리옥시에틸렌-폴리옥시프로필렌 블록 코폴리머를 처리하여 유전자의 세포내 전달효능을 200% 증진시키므로 간암세포내로 유전자를 효율적으로 전달하는 뛰어난 효과가 있다.

    B형 간염 바이러스에 대한 인체 면역기능을 조절하는 합성 펩타이드
    7.
    发明授权
    B형 간염 바이러스에 대한 인체 면역기능을 조절하는 합성 펩타이드 失效
    合成肽调节抗乙型肝炎病毒的免疫活性

    公开(公告)号:KR100236464B1

    公开(公告)日:2000-01-15

    申请号:KR1019960041612

    申请日:1996-09-23

    Abstract: 본 발명은 B형 간염 바이러스(Hepatitis B Virus, 이하 “HBV”라고 약칭함)를 구성하는 4가지 단백질 중에 조절 단백질로서, HBV에 의한 간염이 간암으로 이행되는 기작에 직접적으로 관여하는 것으로 추정되는 X 단백질의 항원 에피토프로 작용하는 새로운 합성 펩타이드에 관한 것으로서, 본 발명의 합성 펩타이드는 세포독성 T 임파구(cytotoxic T lymphocyte, 이하 “CTL”이라고 약칭함) 등을 유도하여 세포 면역기능을 조절할 수 있어 간염이 간경화 및 간암 등으로 이행하는 것을 억제하거나 간암을 치료하는데 유용하게 사용될 수 있다.

Patent Agency Ranking